What's new? Log in Free sign up

Ligand Pharmaceuticals (LGND) News and press releases

Company Profile

News

From Benzinga Pro

Ligand Pharmaceuticals Q4 EPS $1.36 Beats $1.19 Estimate, Sales $50.38M Beat $46.64M Estimate

Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.36 per share which beat the analyst consensus estimate of $1.19 by 14.29 percent. This is a 24.44 percent decrease over earnings of $1.80 per share

Earnings Scheduled For February 22, 2023

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.

Ligand Pharmaceuticals Earnings Preview

Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target

News, Price Target, Reiteration, Analyst Ratings

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $95 price target.

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

Biotech, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General

Sermonix Pharmaceuticals' Lasofoxifene, Will Be Evaluated In A New Study Arm Of The Ongoing I-SPY Endocrine Program Sponsored By Quantum Leap Healthcare Collaborative, In Newly Diagnosed ER+ Invasive Cancer, Lasofoxifene Was In-Licensed From Ligand Pharma

Biotech, News, Health Care, General

The arm is part of the I-SPY 2 Endocrine Optimization Platform (EOP), which is focused on patients with clinically high-risk (stage 2/3) estrogen receptor-positive (ER+)/HER2- breast cancer, but the molecularly

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More

Biotech, News, Small Cap, FDA, Top Stories, General

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.

Press releases

From Benzinga Pro

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31,

Ligand's Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN) Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a

Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial

COLUMBUS, Ohio, and SAN FRANCISCO, Feb. 16, 2023 /PRNewswire/ -- Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative™ today announced that Sermonix's investigational next-generation

Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial

Press Releases, General

COLUMBUS, Ohio, and SAN FRANCISCO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative™ today announced that Sermonix's investigational next-generation

Ligand to Report Fourth Quarter Financial Results on February 22

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report fourth quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, February 22, 2023 and will hold a conference call that same

Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

Potential FDA approval anticipated in the first quarter of 2024, assuming FDA filing acceptance and standard review timelines Molluscum contagiosum is a viral skin infection that affects approximately 6 million people,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.